ABT-869, a promising multi-targeted tyrosine kinase inhibitor: From bench to bedside

by Zhou, J., Chen, C.-S., Goh, B.-C., Albert, D.H.
Published 2011

ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft

by Jasinghe, V.J., Xie, Z., Zhou, J., Khng, J., Poon, L.-F., Senthilnathan, P., Chen, C.-S., Albert, D.H., Davidsen, S.K.
Published 2011

Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway

by Zhou, J., Pan, M., Xie, Z., Loh, S.-L., Bi, C., Tai, Y.-C., Lilly, M., Lim, Y.-P., Han, J.-H., Glaser, K.B., Albert, D.H., Davidsen, S.K., Chen, C.-S.
Published 2014

PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-aml therapy

by Zhou, J., Bi, C., Chng, W.-J., Cheong, L.-L., Liu, S.-C., Mahara, S., Tay, K.-G., Zeng, Q., Li, J., Guo, K., Tan, C.P.B., Yu, H., Albert, D.H., Chen, C.-S.
Published 2014

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

by Zhou, J., Bi, C., Janakakumara, J.V., Liu, S.-C., Chng, W.-J., Tay, K.-G., Poon, L.-F., Xie, Z., Palaniyandi, S., Chen, C.-S., Yu, H., Glaser, K.B., Albert, D.H., Davidsen, S.K.
Published 2011

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

by Zhou, J., Bi, C., Janakakumara, J.V., Liu, S.-C., Chng, W.-J., Tay, K.-G., Poon, L.-F., Xie, Z., Palaniyandi, S., Chen, C.-S., Yu, H., Glaser, K.B., Albert, D.H., Davidsen, S.K.
Published 2011

In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor

by Zhou, J., Khng, J., Jasinghe, V.J., Bi, C., Poon, L.F., Xie, Z., Chen, C.-S., Neo, C.H.S., Pan, M., Yu, H., Yeoh, A.E.-J., Lu, Y., Glaser, K.B., Albert, D.H., Davidsen, S.K.
Published 2011

In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor

by Zhou, J., Khng, J., Jasinghe, V.J., Bi, C., Poon, L.F., Xie, Z., Chen, C.-S., Neo, C.H.S., Pan, M., Yu, H., Yeoh, A.E.-J., Lu, Y., Glaser, K.B., Albert, D.H., Davidsen, S.K.
Published 2011

In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor

by Zhou, J., Khng, J., Jasinghe, V.J., Bi, C., Poon, L.F., Xie, Z., Chen, C.-S., Neo, C.H.S., Pan, M., Yu, H., Yeoh, A.E.-J., Lu, Y., Glaser, K.B., Albert, D.H., Davidsen, S.K.
Published 2011